Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic E. coli O104:H4 from the 2011 German outbreak

BMC Microbiology

Volumn 12, Issue , 2012, Pages

  Corogeanu, Diana ^a   Willmes, Ruben ^a   Wolke, Martina ^a   Plum, Georg ^a   Utermöhlen, Olaf ^a   Krönke, Martin ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b German Center for Infection Research (DZIF)   (Germany)

Author keywords

Antibiotics; Enterohemorrhagic E. coli (EHEC); Shiga toxin producing E. coli (STEC)

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; FOSFOMYCIN; GENTAMICIN; MEROPENEM; RIFAMPICIN; SHIGA TOXIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; DISEASE SEVERITY; ENTEROHEMORRHAGIC ESCHERICHIA COLI; EPIDEMIC; FATALITY; GERMANY; HEMOLYTIC UREMIC SYNDROME; NONHUMAN; SEROTYPE; TRANSCRIPTION INITIATION; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; DISEASE OUTBREAKS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GERMANY; HUMANS; SHIGA TOXIN;

EID: 84864408776     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-12-160     Document Type: Article

References (24)

1. Robert Koch Institute, Report: Final presentation and evaluation of epidemiological findings in the EHEC O104:H4 outbreak, Germany 2011, Berlin 2011 www.rki.de
2. Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections. Serna A, Boedeker EC, Curr Opin Gastroenterol 2008 24 1 38 47 10.1097/MOG.0b013e3282f2dfb8 18043231
3. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Grif K, Dierich MP, Karch H, Allerberger F, Eur J Clin Microbiol Infect Dis 1998 17 11 761 766 10.1007/s100960050181 9923515
4. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Walterspiel JN, Ashkenazi S, Morrow AL, Cleary TG, Infection 1992 20 1 25 29 10.1007/BF01704889 1563808
5. Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in shiga toxin producing Escherichia coli infection. MacConnachie AA, Todd WT, Curr Opin Infect Dis 2004 17 5 479 482 10.1097/00001432-200410000-00013 15353968
6. Hemorrhagic colitis associated with a rare Escherichia coli serotype. Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, Hebert RJ, Olcott ES, Johnson LM, Hargrett NT, et al. N Engl J Med 1983 308 12 681 685 10.1056/NEJM198303243081203 6338386
7. Phage regulatory circuits and virulence gene expression. Waldor MK, Friedman DI, Curr Opin Microbiol 2005 8 4 459 465 10.1016/j.mib.2005.06.001 15979389
8. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Dundas S, Todd WT, Stewart AI, Murdoch PS, Chaudhuri AK, Hutchinson SJ, Clin Infect Dis 2001 33 7 923 931 10.1086/322598 11528561
9. The stimulating effect of fosfomycin, an antibiotic in common use in Japan, on the production/release of verotoxin-1 from enterohaemorrhagic Escherichia coli O157:H7 in vitro. Yoh M, Honda T, Epidemiol Infect 1997 119 1 101 103 10.1017/S0950268897007541 9287950
10. a microbiological study. Bielaszewska M, Mellmann A, Zhang W, Kock R, Fruth A, Bauwens A, Peters G, Karch H: Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, Lancet Infect Dis 2011 11 9 671 676 21703928
11. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Strockbine NA, Marques LR, Newland JW, Smith HW, Holmes RK, O'Brien AD, Infect Immun 1986 53 1 135 140 3522426
12. Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery. Brismar B, Edlund C, Malmborg AS, Nord CE, Antimicrob Agents Chemother 1990 34 3 481 483 10.1128/AAC.34.3.481 2334162
13. Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery. Condon RE, Walker AP, Hanna CB, Greenberg RN, Broom A, Pitkin D, Clin Infect Dis 1997 24 Suppl 2 181 S183 9126691
14. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI, N Engl J Med 2000 342 26 1930 1936 10.1056/NEJM200006293422601 10874060
15. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. Safdar N, Said A, Gangnon RE, Maki DG, Jama 2002 288 8 996 1001 10.1001/jama.288.8.996 12190370
16. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. Martin DL, MacDonald KL, White KE, Soler JT, Osterholm MT, N Engl J Med 1990 323 17 1161 1167 10.1056/NEJM199010253231703 2215593
17. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Bell BP, Griffin PM, Lozano P, Christie DL, Kobayashi JM, Tarr PI, Pediatrics 1997 100 1 12 10.1542/peds.100.1.e12 9200386
18. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Tatara K, Clin Nephrol 1999 52 6 357 362 10604643
19. Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition. Kurioka T, Yunou Y, Harada H, Kita E, Eur J Clin Microbiol Infect Dis 1999 18 8 561 571 10.1007/s100960050348 10517193
20. Role of rifampicin in limiting Escherichia coli O157:H7 Shiga-like toxin expression and enhancement of survival of infected BALB/c mice. Rahal EA, Kazzi N, Kanbar A, Abdelnoor AM, Matar GM, Int J Antimicrob Agents 2011 37 2 135 139 10.1016/j.ijantimicag.2010.10.009 21129928
21. Decrease in Shiga toxin expression using a minimal inhibitory concentration of rifampicin followed by bactericidal gentamicin treatment enhances survival of Escherichia coli O157:H7-infected BALB/c mice. Rahal EA, Kazzi N, Sabra A, Abdelnoor AM, Matar GM, Ann Clin Microbiol Antimicrob 2011 10 34 10.1186/1476-0711-10-34 21906403
22. Epidemic Escherichia coli O104:H4: Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction. Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, Peters G, Karch H, Antimicrob Agents Chemother 2012 56 6 3277 3282 10.1128/AAC.06315-11 22391549
23. Semi-automated fluorogenic PCR assays (TaqMan) forrapid detection of Escherichia coli O157:H7 and other shiga toxigenic E. coli. Sharma VK, Dean-Nystrom EA, Casey TA, Mol Cell Probes 1999 13 4 291 302 10.1006/mcpr.1999.0251 10441202
24. Quantitative microtiter cytotoxicity assay for Shigella toxin. Gentry MK, Dalrymple JM, J Clin Microbiol 1980 12 3 361 366 7012172